Oral drug delivery system and application thereof in field of delivery of protein polypeptide drugs
Through the nanoparticle drug delivery system loading and coating technology, the problem of prone polypeptide drugs being easily degraded and poor permeability after oral administration is solved, slow release and efficient absorption are achieved, and bioavailability is significantly improved.
Patent Information
- Application Number
- CN202411458497.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-18
- Publication Date
- 2024-11-29
AI Technical Summary
After oral administration, protein polypeptide drugs are susceptible to degradation of gastric acid and gastrointestinal enzymes, and are difficult to penetrate the mucus layer of the small intestine, resulting in low bioavailability and limiting their clinical application.
Using a nanoparticle drug delivery system, it consists of a nanoparticle core and shell material. The nanoparticle core contains drug molecules, (2-hydroxypropyl)-β-cyclodextrin, polyethyleneimine and penetration promoters. The shell material is selected from Sodium alginate, etc., form a positively charged cationic polymer through amide reaction, which carries the drug and covers the shell to improve the stability and penetration ability of the drug.
The release of gastric juice and intestinal fluid slowly improves the mucus permeability of drugs and epithelial cell uptake, prolongs intestinal retention time, and significantly improves the oral bioavailability of protein and polypeptide drugs.
Smart Images

Figure CN119033962A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of pharmaceutical formulations, specifically relating to an oral drug delivery system and its application in the delivery of protein and polypeptide drugs. Background Technology
[0002] Protein and peptide drugs are biotechnology drugs that have been widely used in recent years in fields such as diabetes and organ transplant immune rejection. Compared with small molecule drugs, protein and peptide drugs have high specificity and fewer side effects. However, they have poor membrane permeability and are extremely sensitive to enzymes, so these drugs have traditionally been administered primarily by injection in clinical practice. However, injectable formulations are expensive to produce, inconvenient to use, and long-term use increases the psychological and physical burden on patients, significantly reducing patient compliance. Some drugs also cause side effects. For example, protein and peptide drugs such as insulin, liraglutide, exenatide, tesipatide, and smegglutide are mainly administered subcutaneously in clinical practice. This invasive method of administration can cause local reactions at the injection site, such as skin redness, subcutaneous nodules, and subcutaneous fat atrophy. Pain and lumps at the injection site also contribute to poor patient compliance, limiting their clinical application to some extent. Therefore, non-injectable routes of administration for protein and peptide drugs have been extensively studied, including pulmonary, nasal, oral, transdermal, rectal, and oral administration. Among these, oral administration is the most convenient and suitable for patients requiring long-term medication, making oral protein and peptide formulations a hot research area in drug development. However, after oral administration, protein and polypeptide drugs are degraded by gastric acid and various enzymes in the gastrointestinal tract, thus losing their biological activity. Some large molecular drugs have poor permeability and are difficult to penetrate the mucus barrier of the small intestine and be absorbed by the epithelial cells of the small intestine. Consequently, their bioavailability after oral administration is low, making it difficult to achieve the therapeutic purpose and greatly limiting the clinical application of oral protein and polypeptide drugs.
[0003] To address the barrier issues encountered in the oral administration of the aforementioned protein and peptide drugs, several drug carriers have been designed, including ligand-modified carriers. These carriers are modified with functionalized ligands that specifically bind to receptors or transporters on the surface of intestinal epithelial cells, significantly improving cellular uptake efficiency, but resulting in extremely low exocytosis efficiency. Carriers with convertible surface properties—that is, carriers that are electrically neutral in mucus, rapidly penetrating the mucus barrier, and then exposing their positively charged interior at the cell surface—facilitate uptake by intestinal epithelial cells. Additionally, absorption enhancers such as cyclodextrins, sodium decanoate bile salts, fatty acids and their lipids, and chelating agents are incorporated into the carrier design to promote drug absorption. Protease inhibitors such as soybean trypsin inhibitors and aprotinins are also added to protect the drug from degradation by proteases in the gastrointestinal tract and maintain drug stability. Furthermore, enteric coating materials such as Eudragit L100 are added to protect the drug's stability in the acidic environment of the stomach. Nanoparticles are solid particles formed by dispersing drugs and carrier materials using nanotechnology. Their small size allows for controlled drug release, improved in vivo stability of proteins and peptides, and protection against gastrointestinal inactivation. They have also overcome the mucus layer and intestinal epithelial cell barrier, leading to their widespread use in oral drug delivery. Polyethyleneimine, with its strong positive charge, has been widely applied in various fields, including binding nucleotides, binding peptides / proteins, and immunoadjuvants. Some polyethyleneimine-related vaccines have entered preclinical and clinical research stages. The toxicity of polyethyleneimine is related to its molecular weight and polymer structure; generally, low molecular weight polyethyleneimine has low toxicity, while high molecular weight polyethyleneimine has high toxicity. Linear polyethyleneimine is generally less toxic than branched polyethyleneimine. Larger molecular weights result in better transfection efficiency but also higher toxicity. Therefore, modifying the structure of polyethyleneimine, such as using cyclodextrin, can reduce its toxicity. Inspired by nucleic acid drug delivery, cyclodextrin-modified polyethyleneimine shows promising potential for oral delivery of protein and peptide drugs. Summary of the Invention
[0004] To address the shortcomings of existing technologies, this invention provides an oral drug delivery system and its application in the delivery of protein and peptide drugs. The technical solution of this invention is as follows:
[0005] An oral drug delivery system comprising a nanoparticle core and a shell material; the nanoparticle core containing drug molecules, (2-hydroxypropyl)-β-cyclodextrin, polyethyleneimine, and a penetration enhancer.
[0006] Preferably, the shell material is selected from sodium alginate, cellulose acetate phthalate, acrylic resin, hyaluronic acid, or chondroitin sulfate.
[0007] Preferably, the drug molecule is selected from insulin, liraglutide, exenatide, tesipatide, or smegglutide.
[0008] Preferably, the penetration enhancer is selected from sodium decanoate, azone, sodium N-[8-(2-hydroxybenzoyl)amino]octanoate, deoxycholate, taurine, sodium salicylate, or ethylenediaminetetraacetic acid.
[0009] Preferably, the molecular weight of the polyethyleneimine is 600 Da to 10000 Da, and more preferably 600 Da.
[0010] Preferably, the nanoparticle core further includes chitosan.
[0011] More preferably, the drug delivery system comprises a nanoparticle core and a shell material; the nanoparticle core contains insulin or tesipatide, (2-hydroxypropyl)-β-cyclodextrin, polyethyleneimine with a molecular weight of 600 Da, and sodium N-[8-(2-hydroxybenzoyl)amino]octanoate.
[0012] The present invention also provides a method for preparing the oral drug delivery system, comprising the following steps:
[0013] 1) Disperse (2-hydroxypropyl)-β-cyclodextrin and carbonyl diimidazole in an organic solvent. Under the action of a catalyst, the hydroxyl groups on (2-HP)-β-CD are activated by carbonyl diimidazole to form carboxyl groups, which then undergo an amide reaction with polyethyleneimine. After dialyzing and lyophilization, a positively charged cationic polymer CP is obtained.
[0014] 2) Weigh the CP obtained in step 1) and dissolve it in ultrapure water. Then raise the temperature to a certain level and maintain it. Weigh the permeation enhancer and dissolve it in ultrapure water. Add the permeation enhancer aqueous solution to the CP aqueous solution while stirring. After stirring and encapsulating the mixture in the dark at a certain temperature, cool it and dialyze it in purified water. Then freeze-dry it to obtain the CP / permeation enhancer complex.
[0015] 3) Weigh the CP / penetration enhancer complex and dissolve it in ultrapure water. Dissolve the drug molecule in an alkaline solution. Add the drug molecule solution dropwise to the CP / penetration enhancer complex solution while stirring. After stirring for a period of time, a CP / penetration enhancer / drug molecule complex solution is obtained. Dissolve the shell material in ultrapure water. Add the shell material solution dropwise to the CP / penetration enhancer / drug molecule complex solution. After stirring, filter through a microporous membrane and dialyze to remove unencapsulated drug molecules. Freeze dry to obtain the final product.
[0016] Preferably, in step 1), the organic solvent is DMSO, the catalyst is triethylamine, and the molar ratio of (2-hydroxypropyl)-β-cyclodextrin, carbonyl diimidazole and polyethyleneimine is 1:1:1 to 1:10:10.
[0017] Preferably, in step 2), the molar ratio of CP to penetration enhancer is 1:1 to 1:10; the inclusion temperature is 40-70℃, and the time is 1-10h.
[0018] Preferably, in step 3), the mass ratio of the CP / penetration enhancer complex, the drug molecule, and the shell material is 2:1:1 to 3:1:10; the alkaline solution is a 0.01M NaOH aqueous solution.
[0019] The beneficial effects of this invention: This invention provides oral nanoparticles and their carriers for the delivery of protein and peptide drugs. Using (2-hydroxypropyl)-β-cyclodextrin ((2-HP)-β-CD) as a raw material, polyethyleneimine (PEI) of different molecular weights (600-10000) is linked to (2-HP)-β-CD via an amide reaction to obtain a positively charged cationic polymer CP. A penetration enhancer is then loaded into the cyclodextrin lumen using a freeze-drying method. Protein and peptide drugs are then loaded via electrostatic interactions, and a shell is coated onto their surface, constructing an oral nanoparticle delivery system that improves their stability. The preparation of this oral nanoparticle drug delivery system provides a new option for the clinical administration of protein and peptide drugs. The nanoparticle drug delivery system of this invention has the following effects:
[0020] 1. The protein and polypeptide drugs in this invention are encapsulated in nanoparticles and released slowly in gastric and intestinal fluids.
[0021] 2. The oral nanoparticles of the present invention can improve the mucus penetration ability of protein and polypeptide drugs and enhance the uptake of drugs by epithelial cells.
[0022] 3. The outer shell of the present invention prolongs the retention of protein and polypeptide drugs in the intestine, which is beneficial to the effective absorption of the drugs.
[0023] 4. The oral nanoparticles of the present invention can significantly improve the oral bioavailability of protein and polypeptide drugs.
[0024] 5. The oral nanoparticle preparation process of the present invention is simple, mild, and safe, which is conducive to clinical translation and has good application prospects in the field of oral delivery of protein and polypeptide drugs. Attached Figure Description
[0025] Figure 1 Synthesis route of CP
[0026] Figure 2 The 1H NMR spectra of (2-HP)-β-CD, PEI, CP 600 (A) and CP 1800, CP 10000 (B) in heavy water.
[0027] Figure 3 Fourier transform infrared spectra of CP 600(A), CP 1800(B) and CP 10000(C).
[0028] Figure 4 Zeta potentials of CP with different molecular weights.
[0029] Figure 5 Figures showing the in vitro toxicity of different concentrations of CP 600, CP 1800 and CP 10000 on NIH 3T3 cells.
[0030] Figure 6 The UV-Vis absorption spectra (A) and hemolysis rate (B) of different groups of CP are shown.
[0031] Figure 7 UV-Vis absorption spectra (A) and Fourier transform infrared spectra (B) of CP, SNAC, and CP / SNAC; differential scanning calorimetry (C) of CP, SNAC, CP / SNAC, and physical mixtures of CP and SNAC.
[0032] Figure 8 Fourier transform infrared spectra of CP, CP / SA, SNAC, CP / SNAC, INS, CP / INS / SA, and CP / SNAC / INS / SA.
[0033] Figure 9 The UV absorption spectra of CP, CP / SA, SNAC, CP / SNAC, INS, CP / INS / SA, and CP / SNAC / INS / SA are given.
[0034] Figure 10 Transmission electron microscopy and particle size distribution diagrams of CP / INS / SA (A) and CP / SNAC / INS / SA (B), with a scale bar of 100 nm; potential diagrams of CP, CP / SNAC, CP / SNAC / INS, CP / INS / SA and CP / SNAC / INS / SA (C).
[0035] Figure 11 The in vitro release of CP / INS / SA and CP / SNAC / INS / SA at pH 1.2 (A) and pH 6.8 (B).
[0036] Figure 12 This is a diagram showing the cumulative permeability across the mucus layer for INS, CP / INS / SA, and CP / SNAC / INS / SA.
[0037] Figure 13 Flow cytometry graph showing the uptake of free INS, CP / INS / SA, and CP / SNAC / INS / SA by Caco-2 cells.
[0038] Figure 14 The changes in blood glucose in type 1 diabetic rats are shown in (A) and the changes in blood glucose relative to the initial level (B).
[0039] Figure 15 The standard curve for serum insulin is shown in Figure (A); the curves showing the changes in serum insulin concentration over time for oral CP / INS / SA, CP / SNAC / INS / SA, and subcutaneous INS injection are shown in Figure (B).
[0040] Figure 16 Tissue distribution of FITC-labeled CP / INS / SA and CP / SNAC / INS / SA in rats at 2, 4, and 6 hours after oral administration.
[0041] Figure 17 Changes in relative initial blood glucose levels in type 2 diabetic mice treated with CP / SNAC / Ti / SA Detailed Implementation
[0042] The following embodiments are intended to enable those skilled in the art to more fully understand the present invention, but are not intended to limit the invention to the scope of the embodiments described.
[0043] (2-HP)-β-CD:(2-hydroxypropyl)-β-cyclodextrin
[0044]
[0045] CDI: Carbonyldiimidazole
[0046] Ti: Tisipatide
[0047] INS: Insulin
[0048] SA: Sodium alginate
[0049] Polyethyleneimine: SNAC: Sodium N-[8-(2-hydroxybenzoyl)amino]octanoate General preparation method:
[0050] (2-HP)-β-CD{(2-hydroxypropyl)-β-cyclodextrin} and carbonyl diimidazole (CDI) were dispersed in an organic solvent. Under the action of a catalyst, the hydroxyl groups on (2-HP)-β-CD were activated by carbonyl diimidazole to form carboxyl groups, which then reacted with polyethyleneimine to obtain a positively charged cationic polymer CP. CP 600, with good safety profile, was selected through cytotoxicity and blood compatibility tests for the preparation of drug-loaded nanoparticles. Subsequently, the hydrophobic core of CP encapsulates penetration enhancers (such as sodium (2-hydroxypropyl)-β-cyclodextrin decanoate, azone, sodium N-[8-(2-hydroxybenzoyl)amino]octanoate, deoxycholate, taurine cholate, sodium salicylate, and EDTA), and sequentially encapsulates protein and polypeptide drugs (such as insulin, liraglutide, exenatide, tesipatide, and smegglutide) and shell materials (such as sodium alginate, Hep polysaccharide, acrylic resin, hyaluronic acid, and chondroitin sulfate) through electrostatic interactions.
[0051] Example 1: Preparation and Characterization of CP
[0052] In the presence of a catalyst, the hydroxyl group (-OH) on the (2-HP)-β-CD molecule is activated to a carboxyl group (-COOH), which then undergoes an amide reaction with the amino group (-NH2) of polyethyleneimine. The molar ratio of (2-HP)-β-CD:CDI:PEI is 1:10:3.2.
[0053] The specific method is as follows: Weigh 0.5 g of (2-HP)-β-CD and place it in a three-necked flask. Add 6 mL of DMSO and stir in a 25°C water bath at 450 rpm for 2 hours until completely dissolved. Weigh 0.5259 g of CDI and place it in a 10 mL centrifuge tube. Add 3 mL of DMSO, vortex, and then sonicate in an ultrasonic cleaner to dissolve. Add 100 μL of triethylamine as a catalyst to the DMSO solution of (2-HP)-β-CD, and then add the DMSO solution of CDI. Stir for 10 hours under nitrogen protection in the dark. Weigh PEI 6000.5068g and place it in a 10mL centrifuge tube. Add 2mL of DMSO, vortex, and then sonicate in an ultrasonic cleaner for 2 hours to completely dissolve it. Then add 100μL of triethylamine and slowly add the PEI DMSO solution to the 2-HPβ-CD-CDI DMSO solution using a 5mL syringe for 2 hours. This process is carried out in the dark and under nitrogen protection. After stirring overnight for 10 hours, place it in a 1000 molecular weight dialysis bag and dialyze for 3 days. After dialysis, freeze-dry for 3 days to obtain CP 600.
[0054] CP 1800 was placed in a 1000 molecular weight dialysis bag, and CP 10000 was placed in a 3500 molecular weight dialysis bag. Other operations were the same as those for the synthesis of CP600.
[0055] pass 1 The CP was characterized by 1H NMR and IR. Approximately 25 mg of the product was weighed, dissolved in 600 μL L₂O, and its structure was analyzed using a fully digital NMR spectrometer. 1 Its structure was determined by HNMR. Figure 2 The peak H9 (δ = 1.06) is the characteristic peak of CH3- on (2-HP)-β-CD hydroxypropyl, and the peak of H in the -NHCH2CH2- group (δ = 2.42-2.82) is the characteristic peak of PEI 600. The peak of -CONHCH2- (δ = 3.96-3.31) is the characteristic peak of the newly synthesized CP 600, CP 1800, and CP 10000.
[0056] By using a total reflection Fourier transform infrared spectrometer at 4000 cm⁻¹ -1 Up to 500cm -1Record its infrared spectral data within the spectral range and analyze its characteristic functional groups. For example... Figure 3 The results showed that, compared with (2-HP)-β-CD and PEI, CP 600, CP 1800, and CP 10000 were at 1703.81 cm⁻¹. -1 A new absorption peak appeared at the point, which is attributed to the stretching vibration of the carbonyl amide group newly formed during the reaction of (2-HP)-β-CD with PEI.
[0057] In addition, CP was dissolved in distilled water and placed in U-shaped potentiometers. The zeta potential of the nanoparticles was measured using a dynamic light scattering particle size analyzer. Figure 4 As shown, the potentials of CP 600, CP 1800, and CP 10000 are (7.79±0.94) mV, (12.4±1.44) mV, and (15.07±2.66) mV, respectively, all of which are positively charged. This demonstrates that CP 600, CP 1800, and CP 10000 were successfully prepared. Example 2: Safety Determination of CP 600, CP 1800, and CP 10000
[0058] The cationic nature of polymers is one of the determining factors of their cytotoxicity; the positive charge they carry can disrupt cell membrane structures and cause cell damage. This experiment used mouse fibroblasts (NIH 3T3) as a model and employed the MTT assay to evaluate the cytotoxicity of CP. Specifically, cells were seeded at a density of 5000 cells / well in 96-well plates and incubated at 37°C with 5% CO2 until adherence was achieved. Then, 100 μL of culture medium containing different molecular weights of CP was added and incubated for 24 h. The culture medium was then discarded, and 100 μL of LTT solution was added to each well. After incubation for 4 h, the MTT solution was discarded, and 100 μL of LDMSO was added to dissolve the blue-purple formazan. After incubation for 15 min, the absorbance at 570 nm was measured in each well, and cell viability was calculated. Among these, A... sample A0 and A control The absorbance at 570 nm represents the absorbance of the sample group, the PBS control group, and the pure culture medium control group, respectively.
[0059]
[0060] The measurement results are as follows Figure 5The results showed that CP 600 maintained a cell viability of over 90% after incubation at concentrations ranging from 0 to 1000 μg / mL, indicating that CP 600 was virtually non-toxic to cells and met the basic requirements for a drug carrier. However, CP 1800 showed a cell viability of only (76.75 ± 0.75)% at 100 μg / mL, and further decreased to (61.36 ± 0.52)% at 100 μg / mL. Similarly, CP 10000 showed a cell viability of only (72.26 ± 0.94)% at 100 μg / mL, and further decreased to (48.58 ± 0.84)% at 1000 μg / mL. This indicates that although PEI 1800 and PEI 10000 have been modified with cyclodextrin to reduce their cytotoxicity, CP 1800 and CP 10000 are still highly cytotoxic and are not suitable as drug carriers.
[0061] The hemolytic activity of CP 600, CP 1800, and CP 10000 was evaluated using blood compatibility testing. Specifically, blank CP 600 sample solutions at concentrations of 0.4 mg / mL, 1 mg / mL, and 2 mg / mL, and CP 1800 and CP 10000 at concentrations of 0.4 mg / mL were placed in centrifuge tubes. Equal volumes of ultrapure water and PBS were used as positive and negative controls, respectively. 300 μL of freshly prepared red blood cell suspension was added, and after thorough mixing, the mixture was incubated at 37°C for 2 hours and then centrifuged at 3000 rpm for 10 minutes. 200 μL of the supernatant was collected from each well, and the absorbance at 540 nm was measured to calculate the hemolysis rate. (A and A...) PBS and A H2O The absorbance values represent the sample group, the PBS negative control group, and the H2O positive control group, respectively. The hemolysis rate (HR) is calculated using the following formula.
[0062]
[0063] The measurement results are as follows Figure 6 As shown in the figure, the red blood cell suspension mixed with H2O exhibited significant hemolysis, with the supernatant turning red and the volume of the compressed red blood cells decreasing, indicating that most red blood cells had ruptured. The PBS group showed almost no hemolysis, and no significant hemolysis was observed in any of the sample groups. Full-wavelength scanning results showed that the H2O group had the strongest absorption at 540 nm. The hemolysis rates of each group are shown below. Figure 6As shown in Figure B, the hemolysis rates of CP 600 at concentrations of 0.4, 1, and 2 mg / mL are all far below 5%, indicating that CP 600 has good blood compatibility and will not cause hemolysis. The hemolysis rate of CP 1800 at a concentration of 0.4 mg / mL is (3.92±0.44)%, and that of CP 10000 at the same concentration is (7.61±0.29)%. Although the hemolysis rate of CP 1800 is below 5%, its concentration range is relatively narrow, while the hemolysis rate of CP 10000 at a concentration of 0.4 mg / mL is already above 5%. Combined with the cytotoxicity test, this indicates that CP 1800 and CP 10000 are not suitable as drug delivery carriers.
[0064] Example 3: Preparation and Characterization of CP / SNAC
[0065] The inclusion complex was prepared by freeze-drying at a molar ratio of CP to SNAC of 1:1. The specific method is as follows: 50 mg of CP was weighed and dissolved in 20 mL of ultrapure water. The mixture was stirred at 500 rpm for 1 h to ensure complete dissolution. Then, the temperature was raised and maintained at 60 °C. 9.8 mg of SNAC was weighed and dissolved in 5 mL of ultrapure water to ensure complete dissolution. Then, the SNAC aqueous solution was added and stirred in the dark for 5 h at 60 °C. After cooling to room temperature, the mixture was dialyzed in purified water using a 1000 molecular weight dialysis bag for 5 h to remove unencapsulated SNAC. Finally, the mixture was freeze-dried to obtain the final product.
[0066] CP, SNAC, and CP / SNAC were analyzed across the entire wavelength range using an ultraviolet spectrophotometer. Figure 7 A) It can be seen that CP has no ultraviolet absorption in the wavelength range of 200-800 nm, while SNAC shows a characteristic absorption peak of the benzene ring at 296 nm, and CP / SNAC exhibits ultraviolet absorption of the SNAC benzene ring at 305 nm. Using a total reflectance Fourier transform infrared spectrometer at 4000 cm⁻¹... -1 Up to 500cm -1 Record its infrared spectral data within the spectral range, such as Figure 7 As shown in B, compared with CP 600 and CP / SNAC, SNAC has better performance in the fingerprint area (1300-400cm). -1 Many absorption peaks at the specified location disappeared, while the infrared spectra of CP 600 and CP / SNAC almost completely overlapped. Differential scanning calorimetry (DSC) was used to scan CP, SNAC, CP / SNAC, and mixtures of CP and SNAC separately under the following conditions: a temperature range of -20 to 320 °C, a heating rate of 20 °C / min, and a high-purity nitrogen atmosphere. Differential scanning calorimetry curves (…) Figure 7In C), CP 600 showed an endothermic peak at 124℃, SNAC showed an endothermic peak at 197℃, and the physical mixture of CP and SNAC showed an endothermic peak of both CP 600 and SNAC at 197℃. The inclusion compound CP / SNAC showed an endothermic peak of CP 600 at 116℃ and an endothermic peak of SNAC at 56℃. That is, the position of the endothermic peak of SNAC is smaller. The above shows that SNAC was successfully included in the CP 600 structure.
[0067] Example 4: Preparation of CP / SNAC / INS / SA
[0068] The specific method is as follows: Weigh 10 mg of CP / SNAC and dissolve it in 4 mL of ultrapure water. Stir for 1 h to ensure complete dissolution. Dissolve 5 mg of INS in 4 mL of 0.01 M NaOH. Add the INS solution dropwise to the CP / SNAC solution while stirring magnetically at 500 rpm. After stirring for 4 h, dissolve 20 mg of SA in 2 mL of ultrapure water. Mix the solutions using a vortex mixer and then sonicate them in an ultrasonic cleaner until dissolved. Add the SA solution dropwise to the CP / SNAC / INS solution. Stir at 500 rpm for 4 h. After filtering through a 0.45 μm microporous membrane, place the solution in an 8-14 kJ dialysis bag and dialyze for 4 h to remove unencapsulated INS. Finally, freeze-dry the solution to obtain the final product.
[0069] CP, CP / SA, SNAC, CP / SNAC, INS, CP / INS / SA, and CP / SNAC / INS / SA were analyzed using a total reflection Fourier transform infrared spectrometer at 4000 cm⁻¹. -1 Up to 500cm -1 Record its infrared spectral data within the spectral range. The infrared analysis spectra of CP / SNAC / INS / SA are as follows: Figure 8 As shown, compared with CP and CP / SA, the absorption peaks of CP / INS / SA almost overlap with those of CP / SA, and are located at 1703.81 cm⁻¹. -1 The absorption peak of the amide carbonyl group of CP was observed, while some absorption peaks of INS were masked. CP / SNAC / INS / SA almost overlapped with CP / INS / SA, with some SNAC and INS absorption peaks masked. Full-wavelength analysis of CP, CP / SA, SNAC, CP / SNAC, INS, CP / INS / SA, and CP / SNAC / INS / SA was performed using a UV spectrophotometer. Figure 9It can be seen that CP and CP / SA have no ultraviolet absorption in the wavelength range of 200-800nm, while SNAC has ultraviolet absorption at 296nm and INS at 276nm. CP / INS / SA has ultraviolet absorption at 276nm, and CP / SNAC / INS / SA has ultraviolet absorption at 280nm and 305nm. In conclusion, CP / SNAC / INS / SA was successfully prepared.
[0070] Determination of drug loading in CP / SNAC / INS / SA:
[0071] The drug loading of CP / SNAC / INS / SA was determined using a BCA protein quantification kit. The lyophilized formulations were dissolved in ultrapure water to prepare 1 mg / mL solutions. Insulin was dissolved in 0.01 M NaOH, shaken for 30 min, and 20 μL was taken for measurement. The drug loading of insulin was calculated using the following formula. Simultaneously, using insulin as a reference, the drug loading was calculated using a ratio method. Wherein, W... a For the amount of carrier input, W b The quality of the INS package.
[0072]
[0073] The standard curve for BCA is Y = 0.063X + 0.130(R). 2 =0.9930), where X is the protein content and Y is the absorbance. The drug loadings of CP / INS / SA and CP / SNAC / INS / SA, determined by the BCA method, were (27.07±5.83)% and (28.48±0.24)%, respectively.
[0074] Particle size, potential, and morphology characterization of CP / SNAC / INS / SA:
[0075] Drug-loaded nanoparticles were prepared by dialysis. 1 mL of the drug-loaded nanoparticle solution was taken, and the size, potential, and morphology of the nanoparticles were examined using a dynamic light scattering particle size analyzer and a transmission electron microscope, respectively. (CP / INS / SA, CP / SNAC / INS / SA...) Figure 10 The particles are regularly spherical and uniformly distributed. The particle sizes of CP / INS / SA and CP / SNAC / INS / SA are (78.94±2.19) nm and (232.3±6.26) nm, respectively, and the PDI values are (0.20±0.04) and (0.24±0.04), respectively. The potential measurement results are as follows: Figure 10As shown in Figure C, CP is (7.79±0.94) mV, the CP / SNAC potential increases to (12.2±1.55) mV, the CP / SNAC / INS potential changes to (10.3±0.58) mV, the CP / SNAC / INS / SA potential changes to (-43.1±2.19) mV, and the CP / INS / SA potential is (-40.8±0.95) mV. These potential changes also indicate that the drug was successfully encapsulated in the nanoparticles.
[0076] In vitro release behavior study of CP / SNAC / INS / SA:
[0077] Phosphate buffer solutions with pH 1.2 and pH 6.8 were selected to simulate the gastric and intestinal environments, respectively, to investigate the in vitro drug release behavior of CP / INS / SA and CP / SNAC / INS / SA. Specifically, 1 mL of freshly prepared CP / INS / SA or CP / SNAC / INS / SA solution was placed in a dialysis bag (molecular weight 8-14K) and immersed in 15 mL of release medium. Incubation was performed at 37°C and 100 rpm at designed time points: 0, 1, 2, 3, 4, 5, 6, 12, 24, 48, 72, 96, 120, 144, and 168 h. Measurements were taken at pH 1.2 release medium at 0, 1, and 2 h. 1 mL of release medium was removed and 1 mL of the same release medium was added. The INS content was determined using a BCA protein quantification kit. The cumulative INS release amount was calculated using the following formula, where Er is the cumulative INS release amount, m... INS V0 is the INS content in the drug-loaded nanoparticles, and V0 is the total volume of the release medium. e C represents the volume of the release medium retrieved each time. i Let be the drug concentration of the i-th sample.
[0078]
[0079] like Figure 11 As can be seen from A, within 2 hours of release, the cumulative release rates of CP / INS / SA and CP / SNAC / INS / SA reached (23.48±1.98)% and (25.36±3.84)%, respectively. Figure 11 The cumulative release rates of B reached (31.36±1.63)% and (33±1.25)%, respectively. After 24 hours, drug release under pH 6.8 conditions basically entered a plateau phase, with the cumulative release rates of CP / INS / SA and CP / SNAC / INS / SA reaching (36.62±1.58)% and (40.03±1.42)%, respectively. After 168 hours, (39.88±1.48)% and (48.48±0.46)%, respectively, indicating that the solubility of INS increases under intestinal fluid conditions, allowing for further drug release.
[0080] Study on the mucus permeability of CP / SNAC / INS / SA:
[0081] The ability of CP / INS / SA and CP / SNAC / INS / SA to penetrate the mucus layer was evaluated using a Transwell system with a 12-well plate. First, a 4% (m / v) porcine enteric mucin solution was prepared. 350 μL of this 4% porcine enteric mucin solution was evenly spread onto a polycarbonate membrane. Then, 350 μL of freshly prepared INS, CP / INS / SA, and CP / SNAC / INS / SA solutions were carefully spread onto the porcine enteric mucin layer. The receiving chamber was filled with 1.5 mL of pH 6.8 PBS. The Transwell was incubated at 37°C and 100 rpm on a shaker. At predetermined time intervals (2, 4, and 6 h), equal volumes (200 μL) of test samples were removed from the receiving chamber and replenished with an equal volume of preheated pH 6.8 PBS. The fluorescence value was then detected using a fluorescence spectrophotometer, and the FITC content was measured. The cumulative permeability was calculated using the following formula.
[0082]
[0083] Where Er is the cumulative penetration rate of INS, m INS V0 is the FITC content in the drug-loaded nanoparticles, and V0 is the total volume of the release medium. e C represents the volume of the release medium retrieved each time. i Let be the drug concentration of the i-th sample.
[0084] like Figure 12 The results showed that the penetration rate of INS was only (2.32±0.26)% at 2 hours and (4.57±0.23)% at 6 hours, while the penetration rates of CP / INS / SA and CP / SNAC / INS / SA were (7.56±0.67)% and (15.33±6.04)% at 2 hours and (19.56±1.42)% and (37.20±6.05)% at 6 hours, respectively. Within 6 hours, the mucus penetration rates of CP / INS / SA and CP / SNAC / INS / SA were much higher than that of INS, and CP / SNAC / INS / SA was higher than that of CP / INS / SA.
[0085] CP / SNAC / INS / SA uptake studies:
[0086] The uptake of FITC-labeled INS, CP / INS / SA, and CP / SNAC / INS / SA by Caco-2 cells was quantitatively determined by flow cytometry. Caco-2 cells (100,000 cells / well) were seeded in 12-well plates and cultured at 37°C and 5% CO2 for 24 h until adherence. After removing the original culture medium, 1 mL of fresh culture medium containing INS, CP / INS / SA, and CP / SNAC / INS / SA (INS content 48 μg) was added, and the cells were cultured for 1, 2, 4, and 8 h, respectively. The culture medium was then aspirated, and the cells were washed twice with PBS to remove residual drug-containing medium. 300 μL of trypsin was added, and the cells were digested at 37°C for 10 min. Digestion was stopped with 0.7 mL of complete culture medium. After centrifugation at 3000 rpm for 3 min, the cells were washed once with 1 mL of PBS, centrifuged again at 3000 rpm for 3 min, and finally resuspended in 200 μL of PBS for flow cytometry analysis. Compared with the free INS group, at 8 h, Caco-2 cells uptake CP / INS / SA 4.9 times that of INS, and uptake of CP / SNAC / INS / SA 3.6 times that of INS. Figure 13 ).
[0087] Studies on the hypoglycemic effects of CP / SNAC / INS / SA:
[0088] SD rats were randomly divided into 5 groups (n=3): Group A (healthy rats) were given purified water orally (1 mL / 100 g); Group B (free INS) orally (1 mL / 100 g, INS=50 IU / kg); Group C (free INS) was injected subcutaneously (0.1 mL / 100 g, INS=5 IU / kg); Group D (CP / INS / SA) orally (1 mL / 100 g, INS=50 IU / kg); and Group E (CP / SNAC / INS / SA) orally (1 mL / 100 g, INS=50 IU / kg). Rats in each group were fasted for 12 hours before administration. Blood was collected from the tail vein at 0, 1, 2, 4, 6, 8, and 10 hours after administration. Blood glucose concentration was measured using a glucometer and blood glucose test strips. The percentage of blood glucose concentration at different times relative to the initial blood glucose concentration was calculated, and a blood glucose concentration percentage-time curve was plotted to examine the change in blood glucose concentration over time. Figure 14The results showed that at 2 hours, the blood glucose levels in each group relative to the initial blood glucose were (111.89±11.93), (110.80±9.23), (33.97±5.91), (77.50±5.29), and (66.71±19.12)%, respectively. At 4 hours, the blood glucose levels in each group relative to the initial blood glucose were (103.50±5.28), (104.09±9.80), (26.94±4.56), (61.25±8.24), and (53.97±5.91)%, respectively. The blood glucose levels in the control group and the free INS group remained almost unchanged over the next 10 hours, indicating that oral free INS was almost ineffective in lowering blood glucose. In contrast, the subcutaneous insulin injection group gradually recovered after reaching its lowest blood glucose level at hour 4. The blood glucose levels in the CP / INS / SA group and the CP / SNAC / INS / SA group continued to decrease, reaching (56.25±11.61)% and (30.72±7.31)% of the initial blood glucose, respectively, by hour 10. This indicates that both CP / INS / SA and CP / SNAC / INS / SA can produce a sustained hypoglycemic effect, with CP / SNAC / INS / SA showing a superior hypoglycemic effect compared to CP / INS / SA, demonstrating the effectiveness of oral administration.
[0089] Bioavailability studies of CP / SNAC / INS / SA:
[0090] Blood samples were collected from the inner canthus of the eyes of animals in each group at 0, 3, 5, 7, and 10 hours. The blood samples were placed in 1.5 mL centrifuge tubes, allowed to stand at room temperature for 4 hours, and then centrifuged at 1000 × g for 10 minutes to collect serum. The serum was stored at -80℃ for later use. Serum insulin concentrations at different time points were measured using a rat insulin ELISA kit. Blood drug concentration-time curves were plotted, and the bioavailability F relative to subcutaneous insulin injection was calculated based on the area under the blood drug concentration-time curve for each treatment group. The formula for calculating F(%) is as follows.
[0091]
[0092] Where F represents the bioavailability of the oral formulation relative to subcutaneous insulin, AUC oral The area under the plasma concentration-time curve (AUC) for CP / SNAC / INS / SA solutions. SC The area under the plasma concentration-time curve for injected insulin solution. sc This refers to the dosage of INS administered subcutaneously. oral This refers to the oral dosage of CP / SNAC / INS / SA.
[0093] Serum insulin levels at the inner canthus of rat eyes were measured using a double-antibody sandwich enzyme-linked immunosorbent assay (ELISA). A standard curve was plotted using a four-parameter logistic model, with standard concentration as the x-axis and absorbance (OD) value as the y-axis. Figure 15 As shown in Table 1, the serum insulin concentrations of each group were calculated. The results indicate that oral administration of CP / SNAC / INS / SA effectively overcomes barriers such as strong acid, enzymes, and mucus intestinal epithelial cells, reaching peak insulin concentration 3 hours after oral administration, with a relative bioavailability of 8.97%. Table 1: Pharmacokinetic parameters of serum insulin concentrations over time for oral CP / SNAC / INS / SA and subcutaneous INS injection (n=3).
[0094]
[0095] In vivo biodistribution of CP / SNAC / INS / SA:
[0096] Fifteen SD rats were randomly divided into five groups: Group A received 50 IU CP / INS / SA orally; Group B received 50 IU CP / SNAC / INS / SA orally; Group C received 50 IU CP / INS / SA orally; Group D received 50 IU CP / SNAC / INS / SA orally; and Group E served as the control group, receiving no medication. Rats were fasted for 12 hours prior to the experiment, but allowed water. FITC-labeled CP / INS / SA and CP / SNAC / INS / SA were administered to the rats via gavage. At predetermined time intervals (2, 4, and 6 hours), the rats were sacrificed with CO2, and the heart, liver, spleen, lungs, kidneys, stomach, and intestines were removed and imaged using an IVIS spectral system. Figure 16 As shown, in both healthy and diabetic rats, the drug-loaded formulation was almost entirely distributed in the intestines. Moreover, over time, the formulation was mainly distributed in the cecum, while the fluorescence intensity in other parts of the small intestine gradually decreased. Furthermore, it was almost not distributed in the heart, liver, spleen, lungs, kidneys, and stomach. This indicates that the formulation can be well absorbed into the intestines without accumulating in other organs and causing adverse reactions.
[0097] Example 5: Preparation of CP / SNAC / Ti / SA:
[0098] The specific preparation is as follows: 10 mg of CP / SNAC was weighed and dissolved in 4 mL of ultrapure water and stirred for 1 h to ensure complete dissolution. 5 mg of Ti was dissolved in 4 mL of 0.01 M NaOH. INS solution was added dropwise to the CP / SNAC solution under magnetic stirring at 500 rpm. After stirring for 4 h, 20 mg of SA was dissolved in 2 mL of ultrapure water and mixed using a vortex mixer. The mixture was then sonicated in an ultrasonic cleaner until dissolved. SA solution was added dropwise to the CP / SNAC / Ti solution and stirred at 500 rpm for 4 h. After filtering through a 0.45 μm microporous membrane, the solution was dialyzed in an 8-14 K dialysis bag for 4 h to remove unloaded Ti. Finally, the solution was freeze-dried to obtain the final product.
[0099] Determination of particle size, potential, and drug loading of CP / SNAC / Ti / SA:
[0100] Take 1 mL of drug-loaded nanoparticle solution and place it in a cuvette and a U-shaped potentiometer, respectively. Measure the average particle size and zeta potential of the nanoparticles using a dynamic light scattering particle size analyzer. Take 20 μL of drug-loaded nanoparticle solution and determine the Ti content in CP / SNAC / Ti / SA using a BCA kit, and calculate the drug loading. The particle size of CP / SNAC / Ti / SA is (216.1±10.48) nm, the zeta potential is (-34.4±1.55) mV, and the drug loading of CP / SNAC / Ti / SA is (35.3±0.35)%.
[0101] Study on the hypoglycemic effect of CP / SNAC / Ti / SA:
[0102] C57BL / 6J mice fed a high-fat, high-sugar diet for 6 weeks were fasted for 17 hours before being intraperitoneally injected with STZ 100 mg / kg to establish a type 2 diabetes model. They were fed 2 hours after injection, and fasting blood glucose was measured 72 hours later. A blood glucose level >11.0 mM indicated successful establishment of the type 2 diabetes model. The commercially available tesipatide for treating type 2 diabetes patients is 15 mg. Group A received oral PBS (Control); Group B received SC Ti (2.275 mg / kg); Group C received oral gavage with CP / Ti / SA (22.75 mg / kg); and Group D received oral gavage with CP / SNAC / Ti / SA (22.75 mg / kg). Mice in each group were fasted for 12 hours before drug administration. Blood samples were collected from the tail vein at 0, 1, 2, 4, 6, 8, and 10 hours after administration. Blood glucose concentrations were measured using a glucometer and test strips. The percentage of blood glucose concentration at different time points relative to the initial blood glucose concentration was calculated, and a blood glucose concentration percentage-time curve was plotted to examine the changes in blood glucose concentration over time. Subcutaneous injection of tesipatide reduced blood glucose to (14.26±3.26)% of the initial blood glucose at 8 hours. CP / Ti / SA and CP / SNAC / Ti / SA reduced blood glucose to (50.25±4.85)% and (39.71±21.22)% of the initial blood glucose, respectively. This indicates that both CP / Ti / SA and CP / SNAC / Ti / SA formulations have good blood glucose-lowering effects in type 2 diabetic mice, and CP / SNAC / Ti / SA has a better blood glucose-lowering effect than CP / Ti / SA. Figure 17 ).
Claims
1. An oral drug delivery system, which consists of a nanoparticle core and a shell material; the nanoparticle core contains drug molecules, (2-hydroxypropyl)-β-cyclodextrin, polyethyleneimine and a penetration enhancer.
2. The oral drug delivery system according to claim 1, characterized in that: The shell material is selected from sodium alginate, cellulose acetate phthalate, acrylic resin, hyaluronic acid or chondroitin sulfate.
3. The oral drug delivery system according to claim 1, characterized in that: The drug molecule is selected from protein drugs or nucleic acid drugs; preferably, the drug molecule is selected from insulin, liraglutide, exenatide, tesiparatide or semaglutide.
4. The oral drug delivery system according to claim 1, characterized in that: The penetration enhancer is selected from sodium decanoate, azone, sodium N-[8-(2-hydroxybenzoyl)amino]caprylate, deoxycholate, taurocholate, sodium salicylate or ethylenediaminetetraacetic acid.
5. The oral drug delivery system according to claim 1, characterized in that: The molecular weight of the polyethyleneimine is 600Da to 10000Da, preferably 600Da.
6. The oral drug delivery system according to claim 1, characterized in that: The nanoparticle core also includes chitosan.
7. The oral drug delivery system according to claim 1, characterized in that: The oral drug delivery system consists of a nanoparticle core and a shell material; the nanoparticle core contains insulin or tesiparatide, (2-hydroxypropyl)-β-cyclodextrin, polyethyleneimine with a molecular weight of 600 Da and sodium N-[8-(2-hydroxybenzoyl)amino]caprylate.
8. The method for preparing the oral drug delivery system of claim 1, comprising the following steps: 1) (2-hydroxypropyl)-β-cyclodextrin and carbonyldiimidazole are dispersed in an organic solvent. Under the action of a catalyst, the hydroxyl groups on the (2-HP)-β-CD are activated by carbonyldiimidazole to form carboxyl groups, which then undergo an amide reaction with polyethyleneimine, and then dialyzed and freeze-dried to obtain a cationic polymer CP with a positive charge; 2) Weighing the CP prepared in step 1) and dissolving it in ultrapure water, adding an aqueous solution of a penetration enhancer, stirring for inclusion, dialyzing in purified water, and then freeze-drying to obtain a CP / penetration enhancer complex; 3) Weigh the CP / permeation enhancer complex and dissolve it in ultrapure water, dissolve the drug molecules in an alkaline solution, and drop the drug molecule solution into the CP / permeation enhancer complex solution under stirring, and obtain the CP / permeation enhancer / drug molecule complex solution after stirring for a period of time, dissolve the shell material in ultrapure water, and drop the shell material solution into the CP / permeation enhancer / drug molecule complex solution, and after stirring, pass through a microporous filter membrane, dialyze to remove unencapsulated drug molecules, and lyophilize to obtain the product.
9. The preparation method according to claim 8, characterized in that: In the step 1), the organic solvent is DMSO, the catalyst is triethylamine, and the molar ratio of (2-hydroxypropyl)-β-cyclodextrin, carbonyldiimidazole and polyethyleneimine is 1:1:1 to 1:10:
10.
10. The preparation method according to claim 8, characterized in that: In the step 2), the molar ratio of CP: penetration enhancer is 1:1 to 1:10; the inclusion time is 1-10 hours; preferably, in the step 3), the mass ratio of CP / penetration enhancer complex, drug molecule and shell material is 2:1:1 to 3:1:10; the alkaline solution is 0.01M NaOH aqueous solution.
Citation Information
Cited By
Mesoporous polydopamine nanoparticles loaded with texipatide as well as preparation method and application of mesoporous polydopamine nanoparticles
CN119792493A
Mesoporous polydopamine nanoparticles loaded with tisepapeptide, preparation method and application thereof
CN119792493B
